Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22623767 | 1.00 | CRBN (0.44) | CRBNDDB1POLBALDH1A1CHRM2 | |
| SCHEMBL25046231 | 1.00 | CRBN (0.44) | CRBNDDB1POLBALDH1A1CHRM2 | |
| SCHEMBL24315849 | 0.88 | CRBN (0.41) | CRBNDDB1POLB | |
| Hydrochloric Acid SCHEMBL2111827 | 0.82 | CRBN (0.41) | CRBNDDB1POLBALDH1A1CHRM2 | |
| SCHEMBL31435687 | 0.80 | CRBN (0.40) | CRBNDDB1POLB | |
| SCHEMBL25467406 | 0.79 | TLR4 (0.32) | POLB | |
| SCHEMBL22861644 | 0.79 | CRBN (0.35) | CRBNDDB1POLB | |
| SCHEMBL2956440 | 0.77 | MAP3K14 (0.44) | CRBNDDB1POLBALDH1A1TSHR | |
| SCHEMBL11855537 | 0.75 | CRBN (0.50) | CRBNDDB1POLBALDH1A1CHRM2 | |
| SCHEMBL2216388 | 0.71 | NPC1 (0.47) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023235880-A1 | CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023227696-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2023116835-A1 | MULTI-PROTEIN DEGRADATION AGENT HAVING IMIDE SKELETON | 苏州开拓药业股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11639332-B2 | Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases | Amgen (Europe) GmbH (CH) | 2023-05-02 | — | — | US | disclosed |
| US-20200325105-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING AMINO SULFONYL LINKAGE | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| US-10570100-B2 | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2020-02-25 | — | — | US | disclosed |
| WO-2019170750-A1 | METHODS AND COMPOSITIONS OF ISOINDOLINE-1,3-DIONE AND ISOINDOLE PRODRUGS USEFUL FOR TREATING CANCER, ULCERATIVE COLITIS AND RELATED INFLAMMATORY DISEASES | CELGENE INTERNATIONAL II SARL (CH) | 2019-09-12 | — | — | WO | disclosed |
| US-20190270719-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | PRESTWICK CHEMICAL, SAS (FR) | 2019-09-05 | — | — | US | disclosed |
| US-20180194740-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING AMINO SULFONYL LINKAGE | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20160229831-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-08-11 | — | — | US | disclosed |
| US-9133154-B2 | Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140275043-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8093386-B2 | Thioaryl substituted inhibitors of zinc proteases and their use | BRACCO IMAGING S.P.A (IT) | 2012-01-10 | — | — | US | disclosed |
| US-20090239829-A1 | THIOARYL SUBSTITUTED INHIBITORS OF ZINC PROTEASES AND THEIR USE | BRACCO IMAGING SPA (IT) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | CRBN 1/4885DDB1 304/4885POLB 3883/4885 |
| US-20140275043-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | CRBN 2473/4885DDB1 1019/4885POLB 2341/4885 |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CRBN 330/4885DDB1 480/4885POLB 1072/4885 |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | CRBN 2559/4885DDB1 3488/4885POLB 1179/4885 |
| US-20190270719-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | CRBN 3664/4885DDB1 117/4885POLB 26/4885 |
| US-20180194740-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING AMINO SULFONYL LINKAGE | DUT, DPYD, TYMP | CRBN 3137/4885DDB1 75/4885POLB 99/4885 |
| US-20160229831-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | CRBN 2473/4885DDB1 1019/4885POLB 2341/4885 |
| US-20090239829-A1 | THIOARYL SUBSTITUTED INHIBITORS OF ZINC PROTEASES AND THEIR USE | SERPINB1, ZFX, MMP2 | CRBN 1889/4885DDB1 1600/4885POLB 897/4885 |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | CRBN 171/4885DDB1 3993/4885POLB 1265/4885 |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885POLB 2088/4885 |
| US-11639332-B2 | Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases | PDE4A, PDE3B, PDE4B | CRBN 2430/4885DDB1 716/4885POLB 1080/4885 |
| US-20200325105-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING AMINO SULFONYL LINKAGE | DUT, DPYD, TYMP | CRBN 3137/4885DDB1 75/4885POLB 99/4885 |
| US-10570100-B2 | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage | DUT, DPYD, TYMP | CRBN 3137/4885DDB1 75/4885POLB 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.